Status of extended lymph node dissection: Locoregional control is the only way to survive gastric cancer

Journal of Surgical Oncology

Volumn 90, Issue 3, 2005, Pages 153-165

  Hartgrink, Henk H ^a   Van De Velde, Cornelis J H ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Age; Gastric cancer; Lymph node dissection; Pancreatico splenectomy; Volume

Indexed keywords

ANTIINFECTIVE AGENT; CISPLATIN; FLUOROURACIL; FOLIC ACID;

ADOLESCENT; ADULT; AGED; CHILD; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; INFANT; LONG TERM CARE; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MORBIDITY; MORTALITY; PANCREAS RESECTION; PRIORITY JOURNAL; SPLENECTOMY; STOMACH CANCER; SURVIVAL; TREATMENT OUTCOME; TUMOR GROWTH;

CLINICAL TRIALS; GASTRECTOMY; HOSPITAL MORTALITY; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; PANCREATECTOMY; RANDOMIZED CONTROLLED TRIALS; SPLENECTOMY; STOMACH NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 19644383791     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/jso.20222     Document Type: Conference Paper

References (108)

1. Bozzetti F, Marubini E, Bonfanti G, et al.: Subtotal versus total gastrectomy for gastric cancer: Five-year survival rates in a multicenter randomised Italian trial. Ann Surg 1999;230: 170-178.
2. Gouzi JL, Huguier M, Fagniez PL, et al.: Total versus subtotal gastrectomy for adenocarcinoma of the gastric antrum. Ann Surg 1989;209:162-166.
3. Böttcher K, Siewert JR, Roder JD, et al.: Risiko der chirurgischen Therapie des Magencarcinoms in Deutschland: Ergebnisse der Deutschen Magencarcinom-studie 1992. Chirurg 1994;65:298-306.
4. Viste A, Haugstvedt T, Eide GE, et al.: Postoperative complications and mortality after surgery for gastric cancer. Ann Surg 1988;207:7-12.
5. Songun I, Bonenkamp JJ, Hermans J, et al.: Prognostic value of resection-line involvement in patients undergoing curative resections for gastric cancer. Eur J Cancer 1996;32A:433-437.
6. Gunderson LL, Sosin H: Adenocarcinoma of the stomach: Areas of failure in a re-operation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy. Int J Radiat Oncol Biol Phys 1982;8:1-11.
7. Hartgrink HH, van de Velde CJH: Influences of surgery on outcomes in gastric cancer. Surg Oncol Clin North Am 2000; 9:97-117.
8. Hartgrink HH, van de Velde CJH, Putter H, et al.: Extended lymph node dissection for gastric cancer: Who may benefit? Final results of the randomised Dutch Gastric Cancer Group Trial. J Clin Oncol 2004;22:2069-2077.
9. Wölfler A: In: Wilhelm Braumüller, editor. Ueber die Herrn Professor Billroth ausgefuerten Resectionen des carcinomatösen Pylorus. Wien: Braumüller; 1881.
10. Mikulicz J: Beitrage zur Technik der Operation des Magencarcinoms. Arch Klin Chir Berl 1898;1vii:524-532.
11. Cunéo D: De l'envahissement du système lymphtique dans le cancer de l'estomac et de ses consequences chirurgicales. Paris: Steinheil; 1900.
12. Jamieson JK, Dobson JF: The lymphatic system of the stomach. Lancet 1907;1:1061-1066.
13. Coller FA, Kay EB, MacIntyre RS: Regional lymphatic metastases of carcinoma of the stomach. Arch Surg 1941;43: 748-750.
14. Pack GT, McNeer GP: Total gastrectomy for cancer: A collective review of the literature and an original report on 20 cases. Internat Abstr Surg 1943;77:265-299.
15. Eker R: Carcinoma of the stomach. Investigation of the lymphatic spread from gastric carcinomas after total and partial gastrectomy. Act Chir Scand 1951;101:112-126.
16. McNeer G, Sunderland DA, McInnes G, et al.: A more thorough operation for gastric cancer. Anatomical basis and description of technique. Cancer 1951;4:957-967.
17. Gilbertsen VA: The results of treatment for stomach cancer. An appraisal of efforts for more extensive surgery and a report of 1983 cases. Cancer 1969;23:1305-1308.
18. McNeer G, Lawrence W, Ortega LG, et al.: Early results of extended total gastrectomy for cancer. Cancer 1956;9:1153-1159.
19. Macintyre IMC, Akoh JA: Improving survival in gastric cancer: Review of operative mortality in English language publications from 1970. Br J Surg 1991;78:771-776.
20. Akoh JA, Macintyre IMC: Improving survival in gastric cancer: Review of 5-year survival rates in English language publications from 1970. Br J Surg 1992;79:293-299.
21. Kampschöer OHM, Fujii A, Masuda Y: Gastric cancer detected by mass survey - Comparison between mass survey and out-patient detection. Scan J Gastroenterol 1989;24:813-817.
22. Kajitani T: Japanese Research Society for the Study of Gastric Cancer. The general rules for gastric cancer study in surgery and pathology. Jap J Surg 1981;11:127-145.
23. American Joint Committee on Cancer: In: Beahrs OH, Henson DE, Hutter RVP, Kennedy BJ, editors. Manual for staging of cancer, 4th edn. Philadelpia: Lippincott Company; 1992.
24. International Union Against Cancer: In: Hermanek P, Sobin LH, editors. TNM classification of malignant tumors, 4th edn., 2nd revision. Berlin-Heidelberg-New York: Springer; 1992.
25. Wanebo HJ, Kennedy BJ, Chmiel J, et al.: Cancer of the stomach. A patients care study by the American College of Surgeons. Ann Surg 1993;218:583-592.
26. Soga J, Kobayashi K, Saito J, et al.; The role of lymphadenectomy in curative surgery for gastric cancer. World J Surg 1979;3:701-708.
27. Kinoshita T, Maruyama K, Sasako M, et al.: Treatment results of gastric cancer patients: Japanese experience. In: Nishi M, Ichakawa H, Nakajima T, Maruyama K, Tahara E, editors. Gastric cancer. Tokyo, Berlin, Heidelberg: Springer-Verlag; 1993. pp 319-330.
28. Sano T. Sasako M, Yamamoto S, et al.: Gastric Cancer Surgery: Morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy - Japan Clinical Oncology Group Study 9501. J Clin Oncol 2004;22:2767-2773.
29. Maruyama K, Gunven P, Okabayashi K, et al.: Lymph node metastases of gastric cancer. General pattern in 1,931 patients. Ann Surg 1989;210:596-602.
30. Cuschieri A: Recent advances in gastrointestinal malignancy. Ann Chir Gynaecol 1989;78:228-237.
31. Bonenkamp JJ, van de Velde CJH, Kampschöer OHM, et al.: Comparison of factors influencing the prognosis of Japanese, German, and Dutch Gastric cancer patients. World J Surg 1993; 17:410-415.
32. Bonenkamp JJ. Sasako M, Hermans J, et al.: Extended lymphnode dissection for gastric cancer, N Engl J Med 1999;340: 908-914.
33. Nashimoto A, Nakajima T, Furukawa H, et al.: Randomised trial of adjuvant chemotherapy with mitomycin, fluorouracil, and cytosine arabinoside followed by oral fluorouracil in serosa-negative gastric cancer: Japan clinical oncology group 9206-9201. J Clin Oncol 2003;21:2282-2287.
34. Siewert JR, Böttcher K, Roder JD, et al.: Prognostic relevance of systhemic lymph node dissection in gastric carcinoma. Br J Surg 1993;80:1015-1018.
35. Sue-Ling HM, Johnston D, Martin IG, et al.: Gastric cancer: A curable disease in Britain. BMJ 1993;307:591-596.
36. Viste A, Svanes K, Janssen CW, Jr., et al.: Prognostic importance of radical lymphadenectomy in curative resections for gastric cancer. Eur J Surg 1994;160:497-502.
37. Wanebo HJ, Kennedy BJ, Winchester DP, et al.: Gastric carcinoma: Does lymph node dissection alter survival? J Am Coll Surg 1996;183:616-624.
38. Manzoni de G, Verlato G, Guglielmi A, et al.: Prognostic significance of lymph node dissection in gastric cancer. Br J Surg 1996;83:1604-1607.
39. Bösing NM, Goretzki PE, Röher HD: Gastric cancer: Which patients benefit from systematic lymphadenectomy? Eur J Surg Oncol 2000;26:498-505.
40. Lewis WG, Edwards P, Barry JD, et al.: D2 or not D2? The gastrectomy question. Gastric Cancer 2002;5:29-34.
41. Dent DM, Madden MV, Price SK: Randomized comparison of R1 and R2 gastrectomy for gastric carcinoma. Br J Surg 1988; 75:110-112.
42. Robertson CS, Chung SCS, Woods SDS, et al.: A prospective randomized trial comparing R1 subtotal gastrectomy with R3 total gastrectomy for antral cancer. Ann Surg 1994;220: 176-182.
43. Bonenkamp JJ, Songun I, Hermans J, et al.: Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet 1995;345:745-748.
44. Cuschieri A, Fayers P, Fielding J, et al.: Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: Preliminary results of the MRC randomised controlled surgical trial. Lancet 1996;347:995-999.
45. Cuschieri A, Weeden S, Fielding J, et al.: Patient survival after D1 and D2 resections for gastric cancer: Long-term results of the MRC randomized surgical trial. Br J Cancer 1999;79: 1522-1530.
46. Bunt AMG, Hermans J, Boon MC, et al.: Evaluation of the extent of lymphadenectomy in a randomized trial of Western versus Japanese type surgery in gastric cancer. J Clin Oncol 1994;12: 417-422.
47. Degiuli M, Sasako M, Ponti A, et al.: Survival results of a multicentre phase II study to evaluate D2 gastrectomy for gastric cancer. Br J Cancer 2004;90:1727-1732.
48. Degiuli M, Sasako M, Calgaro M, et al.: Morbidity and mortality after D1 and D2 gastrectomy for cancer: Interim analysis of the Italian Gastric Cancer Study Group randomised surgical trial. Eur J Surg Oncol 2004;30:303-308.
49. McCulloch P, Nita ME, Kazi H, et al.: Extended versus limited lymph node dissection technique for adenocarcinoma of te stomach (Cochrane Review). The Cochrane Library. Chichester, UK: Wiley; 2003.
50. Griffith JP, Sue-Ling HM, Martin I, et al.: Preservation of the spleen improves survival after radical surgery for gastric cancer. Gut 1995;36:684-690.
51. Arak A, Kull K: Factors influencing survival of patients after radical surgery for gastric cancer. Acta Oncol 1994;33: 913-920.
52. Lisborg P, Jatzko G, Horn M, et al.: Radical surgery (R2 resection) for gastric cancer. A multivariate analysis. Scand J Gastroenterol 1994;29:1024-1028.
53. Roukos DH, Lorenz M, Encke A: Evidence of survival benefit of extended (D2) lymphadenectomy in Western patients with gastric cancer based on a new concept: A prospective long-term follow-up study. Surgery 1998;123:573-578.
54. Degiuli M, Sasako M, Ponzetti A, et al.: Extended lymph node dissection for gastric cancer: Results of a prospective, multi-centre analysis of morbidity and mortality in 118 consecutive cases. Eur J Surg Oncol 1997;23:310-314.
55. Kodera Y, Yamamura Y, Shimizu Y, et al.: Lack of benefit of combined pancreaticosplenectomy in D2 resection for proximal-third gastric carcinoma. World J Surg 1997;21:622-628.
56. Kitamura K, Nishida S, Ichikawa D, et al.: No survival benefit from combined pancreaticosplenectomy and total gastrectomy for gastric cancer. Br J Surg 1999;86:119-122.
57. Csendes A, Burdiles P, Rojas J, et al.: A prospective randomised study comparing D2 total gastrectomy versus D2 total gastrectomy plus splenectomy in 187 patients with gastric carcinoma. Surgery 2002;131:401-407.
58. Sano T, Yamamoto S, Sasako M: Randomized controlled trial to evaluate splenectomy in total gastrectomy for proximal gastric carcinoma. Jap J Clin Oncol 2002;32:363-364.
59. Edwards P, Blackshaw PG, Barry J, et al.: Randomised comparison of D1 versus modified D2 gastrectomy for gastric cancer. Br J Surg 2003;90:30.
60. Damhuis RA, Tilanus HW: The influence of age on resection rates and postoperative mortality in 2,773 patients with gastric cancer. Eur J Cancer 1995;31A:928-931.
61. Klein Kranenbarg E, van de Velde CJH: Gastric cancer in the elderly. Eur J Surg Oncol 1998;24:384-390.
62. Sasako M, for the Dutch Gastric Cancer Study Group: Risk factors for surgical treatment in the Dutch gastric cancer trial. Br J Surg 1997;84:1567-1571.
63. Maruyama K: The most important prognostic factors for gastric cancer patients: A study using univariate and multivariate analysis. J Gastroenterol 1987;22:133:163.
64. Kodama M, Sugimachi K, Soelima K, et al.: Evaluation of extensive lymph node dissection for carcinoma of the stomach. World J Surg 1981;5:241-248.
65. McCulloch P: Should general surgeons treat gastric carcinoma? An audit of practice and results 1980-1985. Br J Surg 1994;81: 417-420.
66. Bonenkamp JJ, for the Dutch Gastric Cancer group: D1 versus D2 dissection for gastric cancer. Comment on letters. Lancet 1995;345:1517-1518.
67. Bonenkamp JJ, van de Vekle CJH, Sasako M, et al.: R2 compared with R1 resection for gastric cancer: Morbidity and mortality in a prospective, randomized trial. Eur J Surg 1992; 158:413-418.
68. McCulloch P: D1 versus D2 dissection for gastric cancer. Letter, Lancet 1995;345:1516-1517.
69. Parikh D, Johnson M, Chagla L, et al.: D2 gastrectomy: Lessons from a prospective audit of the learning curve. Br J Surg 1996; 83:1595-1599.
70. Maruyama K, Okabayashi K, Kinoshita T: Progress in gastric cancer surgery and its limits of radicality. World J Surg 1987; 11:418-426.
71. Begg CB, Cramer LD, Hoskins WJ, et al.: Impact of hospital volume on operative mortality for major cancer surgery. JAMA 1998;280:1747-1751.
72. Birkmeyer JD, Stukel TA, Siewers AE, et al.: Surgeon volume and operative mortality in the United States. N Engl J Med 2003; 249:2117-2127.
73. Hermans J, Bonenkamp JJ, Boon MC, et al.: Adjuvant therapy after curative resection for gastric cancer: Meta-analysis of randomized trials. J Clin Oncol 1993;11:1441-1447.
74. Hermans J, Bonenkamp JJ: Author update of adjuvant therapy after curative resection for gastric cancer: Meta-analysis of randomized trials. J Clin Oncol 1994;12:878-880.
75. Earle CC, Maroun JA: Adjuvant chemotherapy after curative resection for gastric cancer in non-asian patients: Revisiting a meta-analysis of randomised trials. Eur J Cancer 1999;35:1059-1064.
76. Mari E, Floriani I, Tinazzi A, et al.: Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: A meta-analysis of published randomised trials. Ann Oncol 2000;11: 837-843.
77. Panzini GL, Tassinari I, Mianulli AM, et al.: Meta-analysis of randomised trials of adjuvant chemotherapy in gastric cancer. Ann Oncol 2001;12:1179-1180.
78. Janunger K-G, Hafstrom L, Glimelius B: Chemotherapy in gastric cancer: A review and updated meta-analysis. Eur J Surg 2002;168:597-608.
79. Ajani JA, Ota DM, Jessup M, et al.: Resectable gastric carcinoma: An evaluation of preoperative and postoperative chemotherapy, Cancer 1991;68:1501-1506.
80. Wilke H, Preusser P, Fink U, et al.: Preoperative chemotherapy in locally advanced and non-resectable gastric cancer: A phase II study with etoposide, doxorubicin and cisplatin. J Clin Oncol 1989;7:1318-1326.
81. Kiyabu M, Leichman L, Chandrasoma P: Effect of preoperative chemotherapy on gastric adenocarcinomas: A morphologic study of 25 cases. Cancer 1992;70:2239-2245.
82. Songun I, Keizer HJ, Hermans J, et al.: Chemotherapy for operable gastric cancer: Results of the Dutch randomised FAMTX trial. Eur J Cancer 1999;35:558-562.
83. Hartgrink HH, van de Velde CJH, Putter H, et al.: Neo-adjuvant chemotherapy for operable gastric cancer; long-term results of the Dutch randomised FAMTX trial. Eur J Surg Oncol 2004;30: 643-649.
84. Allum W, Cunningham D, Weeden S, et al.: Peri-operative chemotherapy in operable gastric and lower oesophageal cancer: Randomised controlled trial (the MAGIC Trial). Proc Am Soc Clin Oncol 2003;22:A998.
85. Lowy AM, Feig BW, Janjan N, et al.: A pilot study of preoperative chemoradiotherapy for resectable gastric cancer. Ann Surg Oncol 2001;8:519-524.
86. Macdonald JS, Smalley SR, Benedetti J, et al.: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725-730.
87. Schwarz RE: Postoperative adjuvant chemoradiation therapy for patients with resected gastric cancer: Intergroup 116. J Clin Oncol 2001;19:1879.
88. Cuschieri A: Does chemoradiotherapy after intended curative surgery increase survival of gastric cancer patients. Gut 2002;50: 751.
89. Roukos DH: Adjuvant chemoradiotherapy in gastric cancer: Wave goodbye to extensive surgery? Ann Surg Oncol 2002;9: 220-221.
90. Atkins CD: Adjuvant chemoradiotherapy for gastric cancer, comment. N Engl J Med 2002;346:210.
91. Berney CR, Merrett ND: Adjuvant chemoradiotherapy for gastric cancer, comment. N Engl J Med 2002;346:210.
92. Hundahl SA, Macdonald JS, Benedetti J, et al.: Surgical treatment variation in a prospective, randomized trial of chemoradiotherapy in gastric cancer: The effect of undertreatment. Ann Surg Oncol 2002;9:278-286.
93. Macdonald JS: Which (neo-) adjuvant treatment is appropriate for gastric cancer? Gastrointestinal cancer world congres (Barcelona, June). 2004.
94. Park SH, Kim DY, Heo JS, et al.: Postoperative chemoradiotherapy for gastric cancer. Ann Oncol 2003;14:1373-1377.
95. Sano T, Katai H, Sasako M, et al.: One thousand consecutive gastrectomies without operative mortality. Br J Surg 2002;89: 123.
96. Siewert JR, Böttcher K, Stein HJ, et al.: Relevant prognostic factors in gastric cancer; ten year results of the German gastric cancer study. Ann Surg 1998;228:449-461.
97. Marubini E, Bozzetti F, Miceli R, et al.: Lymphadenectomy in gastric cancer: Prognostic role and therapeutic implications. Eur J Surg Oncol 2002;28:406-412.
98. International Union Against Cancer: In: Sobin LH, Wittekind C, editors. TNM classification of malignant tumors. 5th edn. New York: Wiley-Liss; 1997.
99. Hayashi H, Ochiai T, Suzuki T, et al.: Superiority of a new UICC-TNM staging system for gastric carcinoma. Surgery 2000;127: 129-135.
100. Hermanek P, Altendorf-Hofmann A, Mansmann U, et al.: Improvements in staging of gastric carcinoma using the new edition of TNM classification. Eur J Surg Oncol 1998;24: 536-541.
101. Katai H, Yoshimura K, Maruyama K, et al.: Evaluation of the new international union against cancer TNM staging for gastric cancer. Cancer 2000;88:1796-1800.
102. Kodera Y, Yamamura Y, Shimizu Y, et al.: The number of metastatic lymph nodes: A prognostic determinant for gastric carcinoma in the latest edition of the TNM classification. J Am Coll Surg 1998;187:597-603.
103. Klein Kranenbarg EK, Hermans J, van Krieken JHJM, et al.: Evaluation of the fifth edition of the TNM classification for gastric cancer: improved prognostic value. Br J Cancer 2001;84: 64-71.
104. Songun I, Hermans J, van de Velde CJH, et al.: Expression of oncoproteins and eosinophilic and lymphocytic infiltrates can be used as prognostic factors in gastric cancer. Br J Cancer 1996;74: 1783-1788.
105. Songun I, van de Velde CJH: Can surgical treatment results in gastric cancer be improved? The Oncologist 1996;1:36-40.
106. Songun I, van de Velde CJH, Arends JW, et al.: Classification of gastric carcinoma using the Goseki system provides prognostic information additional to TNM staging. Cancer 1999;85:2114-2118.
107. Weiss M, Kuipers E, Postma C, et al.; Genomic profiling of gastric cancer predicts lymph node status and survival, Oncogene 2003;22:1872-1879.
108. International Union Agains Cancer: In: Sobin LH, Wittekind C, editors. TNM classification of malignant tumors. 6th edn. New York: Wiley-Liss; 2002.